Pharmaceutical USA-based drug developers Tellus Therapeutics, a neonatal care company developing treatments for new-borns in the neonatal intensive care unit (NICU), and Peroxitech, emerging biopharma developing a novel peptide for treating acute lung injury (ALI), have announced the closing of Series A financings led by the Perceptive Xontogeny Venture Fund. 14 December 2022